BGBIO Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BerGenBio ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 10.00 |
| 52 Week High | NOK 35.80 |
| 52 Week Low | NOK 8.50 |
| Beta | 1.61 |
| 11 Month Change | -10.91% |
| 3 Month Change | -15.97% |
| 1 Year Change | -2.72% |
| 33 Year Change | -99.51% |
| 5 Year Change | -99.30% |
| Change since IPO | -99.60% |
Recent News & Updates
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?
Sep 21
Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky
Jun 02Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely
Dec 07Recent updates
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?
Sep 21Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky
Jun 02Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely
Dec 07BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely
Aug 24BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely
Feb 06Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?
Sep 26Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?
Jun 11Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?
Feb 17We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate
Sep 21It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year
Mar 13We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow
Feb 11What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?
Dec 21Shareholder Returns
| BGBIO | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | 10.3% | -2.3% | 0.2% |
| 1Y | -2.7% | -62.1% | -0.5% |
Return vs Industry: BGBIO exceeded the Norwegian Biotechs industry which returned -62.1% over the past year.
Return vs Market: BGBIO underperformed the Norwegian Market which returned -0.5% over the past year.
Price Volatility
| BGBIO volatility | |
|---|---|
| BGBIO Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 11.3% |
| 10% least volatile stocks in NO Market | 2.7% |
Stable Share Price: BGBIO's share price has been volatile over the past 3 months.
Volatility Over Time: BGBIO's weekly volatility has decreased from 14% to 9% over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 15 | Martin Olin | www.bergenbio.com |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors.
BerGenBio ASA Fundamentals Summary
| BGBIO fundamental statistics | |
|---|---|
| Market cap | NOK 390.87m |
| Earnings (TTM) | -NOK 155.40m |
| Revenue (TTM) | NOK 521.00k |
750.2x
P/S Ratio-2.5x
P/E RatioIs BGBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGBIO income statement (TTM) | |
|---|---|
| Revenue | NOK 521.00k |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 521.00k |
| Other Expenses | NOK 155.93m |
| Earnings | -NOK 155.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 13, 2024
| Earnings per share (EPS) | -3.98 |
| Gross Margin | 100.00% |
| Net Profit Margin | -29,828.22% |
| Debt/Equity Ratio | 0% |
How did BGBIO perform over the long term?
See historical performance and comparison